Rossari Biotech Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI Depositories Regulations.

Regulatory Filing Details

The company filed the compliance certificate on April 3, 2026, addressing both BSE Limited and National Stock Exchange of India Limited. The submission was made under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Registrar Confirmation

MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, provided confirmation regarding the dematerialisation process. The registrar confirmed that all securities received from depository participants during the quarter were processed according to regulatory requirements.

Key confirmations from the registrar include:

• Securities received for dematerialisation were confirmed to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Names of depositories were substituted in the register of members as registered owners
• All securities are listed on stock exchanges where earlier issued securities are listed

Notable Quarter Activity

The registrar specifically noted that no remat requests were received for processing during the quarter ended March 31, 2026. This indicates no requests for conversion of shares from electronic to physical form were made during this period.

Company Information

Rossari Biotech Limited operates as an ISO 9001:2015 & 14001:2015 certified company with CIN L24100MH2009PLC194818. The company maintains its registered office in Mumbai and operates manufacturing facilities in Silvassa and Gujarat.

The compliance certificate filing demonstrates the company's adherence to regulatory requirements for share dematerialisation processes and maintains transparency with stock exchange authorities and shareholders.

Rossari Biotech Limited announced a significant milestone in its capacity expansion plans as its material subsidiary Unitop Chemicals Private Limited successfully commissioned additional ethoxylation capacity at its Dahej facility. The development marks the completion of the second phase of a major expansion project that strengthens the company's manufacturing capabilities in the specialty chemicals sector.

Capacity Expansion Details

Unitop Chemicals has commissioned the remaining 15,000 MTPA ethoxylation capacity out of the total planned 30,000 MTPA expansion at its facility in Dahej, effective from March 31, 2026. This represents the completion of the capacity addition project that was previously announced through multiple regulatory filings.

Enhanced Production Capabilities

With this latest commissioning, Unitop's total installed ethoxylation capacity now stands at 66,000 MTPA. The expansion significantly enhances the subsidiary's production capabilities and positions it to better serve growing market demand for specialty chemical products.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously provided updates on this capacity expansion project through intimations dated October 19, 2023, October 17, 2024, and September 26, 2025, demonstrating consistent progress tracking and regulatory compliance.

Strategic Significance

The successful commissioning of this additional capacity represents a key milestone for Rossari Biotech's subsidiary operations. Unitop Chemicals, being a material subsidiary of the company, plays a crucial role in the overall business strategy. The expanded ethoxylation capacity at the Dahej facility enhances the company's ability to meet increasing demand in the specialty chemicals market and supports its growth objectives in this segment.